Is A Boston University Professor’s Plan For Lower Drug Costs Viable? – Forbes

“While the costs of prescription drugs have been controversial for a long time, the launch of Gilead’s breakthrough hepatitis C drug, Sovaldi, has intensified the debate. There have recently been a spate of attacks on the pricing of new drugs from a variety of places including the BBC and the WHO. However, one critique in particular attracted my interest. Entitled “Health care expert says drugmakers are lying about why drugs cost so much,” by Don Seiffert of the Boston Business Journal, this piece goes beyond the attacks to propose a solution.”

Read more – Forbes